Department of Nuclear Medicine & PET Research, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Target Oncol. 2010 Jun;5(2):95-112. doi: 10.1007/s11523-010-0146-5. Epub 2010 Jul 14.
Targeted therapy has significantly improved the perspectives of patients with metastatic renal cell cancer (mRCC). Frequently, these new molecules cause disease stabilization rather than substantial tumor regression. As treatment options expand with the growing number of targeted agents, there is an increasing need for surrogate markers to early assess tumor response. Here, we review the currently available imaging techniques and response evaluation criteria for the assessment of tumor response in mRCC patients. For computed tomography (CT), different criteria are discussed including the Response Evaluation Criteria in Solid Tumors (RECIST), the Choi criteria, the modified Choi criteria, and the size and attenuation CT (SACT) criteria. Functional imaging modalities are discussed, such as dynamic contrast-enhanced CT (DCE-CT), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), dynamic contrast-enhanced ultrasonography (DCE-US), and positron emission tomography (PET).
靶向治疗显著改善了转移性肾细胞癌（mRCC）患者的预后。这些新分子经常引起疾病稳定，而不是实质性肿瘤消退。随着靶向药物数量的增加，治疗选择不断增加，因此需要替代标志物来早期评估肿瘤反应。在这里，我们回顾了目前用于评估 mRCC 患者肿瘤反应的成像技术和反应评估标准。对于计算机断层扫描（CT），讨论了不同的标准，包括实体瘤反应评估标准（RECIST）、Choi 标准、改良 Choi 标准以及大小和衰减 CT（SACT）标准。还讨论了功能成像方式，如动态对比增强 CT（DCE-CT）、动态对比增强磁共振成像（DCE-MRI）、动态对比增强超声（DCE-US）和正电子发射断层扫描（PET）。
